Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Calcif Tissue Int. 2018 May 12;103(4):380–387. doi: 10.1007/s00223-018-0432-2

Table 2. Age- and Multivariable-Adjusted Relative Risks for Clinical Vertebral Fracture According to PPI and H2-Receptor Antagonist Use*.

PPI Use

No Yes
Cases of Vertebral Fracture (n) 426 121
Person-years (n) 523,600 83,248
Age-adjusted Relative Risk (95% CI) 1.00 (reference) 1.44 (1.17, 1.77)
Multivariate Relative Risk (95% CI) (Model without osteoporosis) 1.00 (reference) 1.36 (1.11, 1.68)
Multivariate Relative Risk (95% CI) †† (Model with osteoporosis) 1.00 (reference) 1.29 (1.04, 1.59)

H2-Receptor Antagonist Use

No Yes
Cases of Vertebral Fracture (n) 503 44
Person-years (n) 569,267 37,580
Age-adjusted Relative Risk (95% CI) 1.00 (reference) 1.34 (0.98, 1.82)
Multivariate Relative Risk (95% CI) (Model without osteoporosis) 1.00 (reference) 1.26 (0.92, 1.72)
Multivariate Relative Risk (95% CI) †† (Model with osteoporosis) 1.00 (reference) 1.22 (0.90, 1.67)
*

PPI and H2-Receptor Antagonist use were updated throughout the analysis period (2002-2014). Relative risks are for the risk of vertebral fracture compared with the group that did not use PPIs or H2-Receptor Antagonists.

The multivariate model includes body mass index, race, physical activity, history of falls, smoking status, alcohol intake, supplemental calcium intake, quintiles of diet calcium intake, total vitamin D intake, vitamin A intake, total protein intake, history of diabetes, postmenopausal hormone use, and recent physical exam.

††

The multivariate model includes body mass index, race, physical activity, history of falls, smoking status, alcohol intake, supplemental calcium intake, quintiles of diet calcium intake, total vitamin D intake, vitamin A intake, total protein intake, history of diabetes, self-reported osteoporosis, postmenopausal hormone use, and recent physical exam.